Stock OMCL OMNICELL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Omnicell, Inc.

Equities

OMCL

US68213N1090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
27.86 USD +2.69% Intraday chart for Omnicell, Inc. +0.11% -25.96%
Apr. 16 Omnicell, Inc. Announces XT Amplify CI
Feb. 29 Omnicell, Inc. Announces Executive Changes CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,427 5,078 7,929 2,251 1,711 1,279 - -
Enterprise Value (EV) 1 3,427 5,059 8,068 2,487 1,813 1,331 1,270 1,279
P/E ratio 57.1 x 162 x 111 x 420 x -83.6 x -67 x 148 x -253 x
Yield - - - - - - - -
Capitalization / Revenue 3.82 x 5.69 x 7 x 1.74 x 1.49 x 1.2 x 1.13 x 1.11 x
EV / Revenue 3.82 x 5.67 x 7.13 x 1.92 x 1.58 x 1.25 x 1.12 x 1.11 x
EV / EBITDA 20.5 x 31.7 x 35.1 x 12.9 x 13.1 x 13.3 x 9.71 x 9.21 x
EV / FCF 26.5 x 31 x 39.8 x 146 x 14.4 x 132 x 60.4 x 19.2 x
FCF Yield 3.77% 3.22% 2.51% 0.69% 6.96% 0.76% 1.66% 5.21%
Price to Book 4.07 x 5.43 x 6.95 x 2 x - 1.1 x 1.12 x -
Nbr of stocks (in thousands) 41,938 42,307 43,943 44,650 45,469 45,923 - -
Reference price 2 81.72 120.0 180.4 50.42 37.63 27.86 27.86 27.86
Announcement Date 2/6/20 2/1/21 2/14/22 2/28/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 897 892.2 1,132 1,296 1,147 1,064 1,130 1,154
EBITDA 1 166.8 159.4 229.6 192.9 137.9 99.91 130.8 138.9
EBIT 1 78.35 35.53 89.51 -2.323 81.52 35.67 55.9 61.04
Operating Margin 8.73% 3.98% 7.91% -0.18% 7.11% 3.35% 4.95% 5.29%
Earnings before Tax (EBT) 1 73.93 29.35 66.01 -2.453 -20.11 -35.15 14.67 -7.072
Net income 1 61.34 32.19 77.85 5.648 -20.37 -19.03 8.887 -5.304
Net margin 6.84% 3.61% 6.88% 0.44% -1.78% -1.79% 0.79% -0.46%
EPS 2 1.430 0.7400 1.620 0.1200 -0.4500 -0.4160 0.1880 -0.1100
Free Cash Flow 1 129.1 163 202.8 17.04 126.1 10.1 21.04 66.67
FCF margin 14.39% 18.27% 17.92% 1.31% 10.99% 0.95% 1.86% 5.78%
FCF Conversion (EBITDA) 77.39% 102.28% 88.34% 8.83% 91.44% 10.11% 16.08% 47.99%
FCF Conversion (Net income) 210.5% 506.39% 260.56% 301.72% - - 236.7% -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/6/20 2/1/21 2/14/22 2/28/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 296.4 311 318.8 331.4 348.1 297.7 290.6 299 298.7 258.8 236.8 261.9 280.8 284.6 261.3
EBITDA 1 65.94 52.01 50.36 56.06 60.61 25.86 26.78 46.82 40.54 23.74 3.642 24.33 33.47 38.57 28.39
EBIT 1 29.39 11.59 5.084 12.48 18.46 -38.36 13.3 31.68 27.21 9.338 -11.04 8.627 17.09 21.02 9.832
Operating Margin 9.92% 3.73% 1.59% 3.77% 5.31% -12.89% 4.58% 10.6% 9.11% 3.61% -4.66% 3.29% 6.09% 7.38% 3.76%
Earnings before Tax (EBT) 1 23.33 6.804 4.97 10.77 17.32 -35.51 -21.18 12.21 7.382 -18.52 -30.63 -14.98 -2.124 9.22 -1.216
Net income 1 29.32 13.98 8.213 9.069 16.77 -28.41 -15 3.451 5.553 -14.38 -22.46 -6.455 1.693 8.186 3.23
Net margin 9.89% 4.5% 2.58% 2.74% 4.82% -9.54% -5.16% 1.15% 1.86% -5.55% -9.48% -2.46% 0.6% 2.88% 1.24%
EPS 2 0.6100 0.2800 0.1700 0.2000 0.3700 -0.6400 -0.3300 0.0800 0.1200 -0.3200 -0.4940 -0.1420 0.0380 0.1760 0.0733
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/2/21 2/14/22 4/28/22 8/4/22 11/2/22 2/28/23 5/2/23 8/1/23 11/2/23 2/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 139 236 102 51.7 - -
Net Cash position 1 - 18.7 - - - - 9.8 -
Leverage (Debt/EBITDA) - - 0.6058 x 1.225 x 0.7375 x 0.5177 x - -
Free Cash Flow 1 129 163 203 17 126 10.1 21 66.7
ROE (net income / shareholders' equity) 8.05% 3.55% 16.6% 12% 7.47% 4.29% 5.82% -
ROA (Net income/ Total Assets) 5.28% 2.1% 8.83% 6.26% 3.91% 2.27% 3.12% -
Assets 1 1,161 1,533 881.9 90.21 -521.5 -840.2 285.1 -
Book Value Per Share 2 20.10 22.10 26.00 25.30 - 25.40 24.90 -
Cash Flow per Share 2 - - - 1.690 4.010 2.340 2.670 -
Capex 1 15.9 22.8 29 60.7 55 38.5 39 47.2
Capex / Sales 1.77% 2.56% 2.56% 4.69% 4.8% 3.62% 3.45% 4.09%
Announcement Date 2/6/20 2/1/21 2/14/22 2/28/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Omnicell, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
27.86 USD
Average target price
33.29 USD
Spread / Average Target
+19.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.25B
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.18B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.33B
SECTRA AB Stock Sectra AB
+22.93% 3.83B
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.23B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.12B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 912M
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 859M
VERADIGM INC. Stock Veradigm Inc.
-24.12% 856M
SURGICAL SCIENCE SWEDEN AB Stock Surgical Science Sweden AB
-18.47% 661M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. OMCL Stock
  4. Financials Omnicell, Inc.